草药减肥补充剂诱导体内代谢变化 表明氧化应激
Emily C Davies1,2, Garth L Maker1,2, Ian F Musgrave3
1Centre for Computational and Systems Medicine, Murdoch University, Perth, WA 6150, Australia.
Metabolites
|September 26, 2025
概括
许多草药减肥补充剂 (WLS) 在肝脏和肠道细胞中引起毒性. 核磁共振 (NMR) 光谱学揭示了代谢障碍,表明潜在的氧化应激和需要改进安全查.
科学领域:
- 毒理学 毒理学 毒理学
- 代谢学 代谢学 代谢学
- 药理学 药理学 是一个学科.
背景情况:
- 全球肥胖率的上升与草药减肥补充剂 (WLS) 的使用增加有关.
- 关于WLS的有效性和安全性的证据有限,越来越多的不良事件报告.
- 需要识别有毒的WLS并了解它们对细胞的影响.
研究的目的:
- 确定哪些WLS在体外引起毒性.
- 使用1H核磁共振 (NMR) 光谱分析WLS诱导的人类肝脏和肠道细胞中的代谢变化.
主要方法:
- 在澳大利亚可用的WLS体外分析.
- 在HepG2 (肝) 和Caco-2 (肠) 细胞系中评估了毒性.
- 1H NMR光谱和O-PLS-DA用于受影响细胞的代谢概况.
主要成果:
- 所有10个WLS测试都减少了肠道细胞活力;9个减少了肝细胞活力.
- 代谢分析揭示了治疗细胞中氨基酸,葡萄糖,碳酸盐和氨基酸的显著变化.
- 检测到细胞内蛋白质,能量代谢和膜脂质的干扰,表明氧化应激.
结论:
- 草药减肥补充剂诱导显著的细胞毒性和代谢障碍.
- 生物化学变化表明潜在的氧化应激,突出了安全问题.
- 建议加强WLS的市场前查,以保护消费者健康.
更多相关视频
06:19Evaluation of Oxidative Stress in Biological Samples Using the Thiobarbituric Acid Reactive Substances Assay
Published on: May 12, 2020
31.6K
13:09Rapid Model to Evaluate the Anti-Obesity Potential of a Combination of Syzygium aromaticum Clove and Cuminun cyminum Cumin on C57BL6/j Mice Fed High-Fat Diet
Published on: July 31, 2021
4.0K
相关概念视频
Phase I Oxidative Reactions: Overview
Phase I biotransformation, or functionalization, is a crucial chemical process that converts drugs and other xenobiotics into more water-soluble forms, facilitating expulsion from the body. It involves oxidative, reductive, and hydrolytic reactions that add or unveil polar functional groups on lipophilic substrates. Key players in phase I reactions are the mixed-function oxidases. Situated in liver cell microsomes, these enzymes predominantly carry out drug metabolism. They require molecular...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
